• 1
    Iozzo RV, Goldoni S, Berendsen A & Young MF (2011) Small leucine-rich proteoglycans. In Extracellular Matrix: An Overview (Mecham RP, ed.), pp. 197231. Springer, Heidelberg.
  • 2
    Merline R, Nastase MV, Iozzo RV & Schaefer L (2012) Small leucine-rich proteoglycans: multifunctional signaling effectors. In Extracellular Matrix: Pathobiology and Signaling (Karamanos N, ed), pp. 185196. Walter de Gruytier, Berlin.
  • 3
    Neill T, Schaefer L & Iozzo RV (2012) Decorin, a guardian from the matrix. Am J Pathol 181, 380387.
  • 4
    Danielson KG, Fazzio A, Cohen I, Cannizzaro LA, Eichstetter I & Iozzo RV (1993) The human decorin gene: intron–exon organization, discovery of two alternatively spliced exons in the 5′ untranslated region, and mapping of the gene to chromosome 12q23. Genomics 15, 146160.
  • 5
    Santra M, Danielson KG & Iozzo RV (1994) Structural and functional characterization of the human decorin gene promoter. A homopurine–homopyrimidine S1 nuclease-sensitive region is involved in transcriptional control. J Biol Chem 269, 579587.
  • 6
    Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE & Iozzo RV (1997) Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 136, 729743.
  • 7
    Kalamajski S & Oldberd Å (2010) The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol 29, 248253.
  • 8
    Reed CC & Iozzo RV (2002) The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J 19, 249255.
  • 9
    Keene DR, San Antonio JD, Mayne R, McQuillan DJ, Sarris G, Santoro SA & Iozzo RV (2000) Decorin binds near the C terminus of type I collagen. J Biol Chem 275, 2180121804.
  • 10
    Zhang G, Ezura Y, Chervoneva I, Robinson PS, Beason DP, Carine ET, Soslowsky LJ, Iozzo RV & Birk DE (2006) Decorin regulates assembly of collagen fibrils and acquisition of biomechanical properties during tendon development. J Cell Biochem 98, 14361449.
  • 11
    Robinson PS, Lin TW, Jawad AF, Iozzo RV & Soslowsky LJ (2004) Investigating tendon fascicle structure–function relationship in a transgenic age mouse model using multiple regression models. Ann Biomed Eng 32, 924931.
  • 12
    Robinson PS, Huang TF, Kazam E, Iozzo RV, Birk DE & Soslowsky LJ (2005) Influence of decorin and biglycan on mechanical properties of multiple tendons in knockout mice. J Biomech Eng 127, 181185.
  • 13
    Merline R, Moreth K, Beckmann J, Nastase MV, Zeng-Brouwers J, Tralhão JG, Lemarchand P, Pfeilschifter J, Schaefer RM, Iozzo RV, et al. (2011) Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and microRNA-21. Sci Signal 4, ra75, doi:10.1126/scisignal.2001868.
  • 14
    Merline R, Lazaroski S, Babelova A, Tsalastra-Greul W, Pfeilschifter J, Schluter KD, Gunther A, Iozzo RV, Schaefer RM & Schaefer L (2009) Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J Physiol Pharmacol 60 (Suppl 4), 513.
  • 15
    Liang FT, Wang T, Brown EL, Iozzo RV & Fikrig E (2004) Protective niche for Borrelia burgdorferi to evade humoral immunity. Am J Pathol 165, 977985.
  • 16
    Moreth K, Iozzo RV & Schaefer L (2012) Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. Cell Cycle 11, 20842091.
  • 17
    Nikitovic D, Aggelidakis J, Young MF, Iozzo RV, Karamanos NK & Tzanakakis GN (2012) The biology of small leucine-rich proteoglycans in bone pathophysiology. J Biol Chem 287, 3392633933.
  • 18
    Seidler DG, Mohamed NA, Bocian C, Stadtmann A, Hermann S, Schäfers K, Schäfers M, Iozzo RV, Zarbock A & Götte M (2011) The role for decorin in delayed-type hypersensitivity. J Immunol 187, 61086199.
  • 19
    Seidler DG (2012) The galactosaminoglycan-containing decorin and its impact on diseases. Curr Opin Struct Biol 22, 578582.
  • 20
    Häkkinen L, Strassburger S, Kahari VM, Scott PG, Eichstetter I, Iozzo RV & Larjava H (2000) A role for decorin in the structural organization of periodontal ligament. Lab Invest 80, 18691880.
  • 21
    Järveläinen H, Puolakkainen P, Pakkanen S, Brown EL, Höök M, Iozzo RV, Sage H & Wight TN (2006) A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen 14, 443452.
  • 22
    Schönherr E, Sunderkotter C, Schaefer L, Thanos S, Grässel S, Oldberg Å, Iozzo RV, Young MF & Kresse H (2004) Decorin deficiency leads to impaired angiogenesis in injured mouse cornea. J Vasc Res 41, 499508.
  • 23
    Williams KJ, Qiu G, Usui HK, Dunn SR, McCue P, Bottinger E, Iozzo RV & Sharma K (2007) Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol 171, 14411450.
  • 24
    Baghy K, Dezsó K, László V, Fullár A, Péterfia B, Paku S, Nagy P, Schaff Z, Iozzo RV & Kovalszky I (2011) Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Lab Invest 91, 439451.
  • 25
    Goldoni S, Owens RT, McQuillan DJ, Shriver Z, Sasisekharan R, Birk DE, Campbell S & Iozzo RV (2004) Biologically active decorin is a monomer in solution. J Biol Chem 279, 66066612.
  • 26
    Rühland C, Schönherr E, Robenek H, Hansen U, Iozzo RV, Bruckner P & Seidler DG (2007) The glycosaminoglycan chain of decorin plays an important role in collagen fibril formation at the early stages of fibrillogenesis. FEBS J 274, 42464255.
  • 27
    Jungmann O, Nikolovska K, Stock C, Schulz J-N, Eckes B, Riethmüller C, Owens RT, Iozzo RV & Seidler DG (2012) The dermatan sulfate proteoglycan decorin modulates α2β1 integrin and vimentin intermediate filament system during collagen synthesis. PLoS ONE 7, e50809.
  • 28
    Theocharis AD, Tzanakakis G & Karamanos NK (2010) Proteoglycans in health and disease: novel proteoglycan roles in malignancy and their pharmacological targeting. FEBS J 277, 39043923.
  • 29
    Iozzo RV & Cohen I (1993) Altered proteoglycan gene expression and the tumor stroma. Cell Mol Life Sci 49, 447455.
  • 30
    Goldoni S & Iozzo RV (2008) Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123, 24732479.
  • 31
    Iozzo RV & Sanderson RD (2011) Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15, 10131031.
  • 32
    Feugaing DDS, Götte M & Viola M (2013) More than matrix: the multifaceted role of decorin in cancer. Eur J Cell Biol 92, 111.
  • 33
    Iozzo RV, Moscatello D, McQuillan DJ & Eichstetter I (1999) Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274, 44894492.
  • 34
    Santra M, Reed CC & Iozzo RV (2002) Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping with but distinct from the EGF-binding epitope. J Biol Chem 277, 3567135681.
  • 35
    Zhu J-X, Goldoni S, Bix G, Owens RA, McQuillan D, Reed CC & Iozzo RV (2005) Decorin evokes protracted internalization and degradation of the EGF receptor via caveolar endocytosis. J Biol Chem 280, 3246832479.
  • 36
    Buraschi S, Pal N, Tyler-Rubinstein N, Owens RT, Neill T & Iozzo RV (2010) Decorin antagonizes Met receptor activity and downregulates β-catenin and Myc levels. J Biol Chem 285, 4207542085.
  • 37
    Adany R, Heimer R, Caterson B, Sorrell JM & Iozzo RV (1990) Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. J Biol Chem 265, 1138911396.
  • 38
    Bi X, Tong C, Dokendorff A, Banroft L, Gallagher L, Guzman-Hartman G, Iozzo RV, Augenlicht LH & Yang W (2008) Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis 29, 14351440.
  • 39
    Bi X, Pohl NM, Yang GR, Gou Y, Guzman G, Kajdacsy-Balla A, Iozzo RV & Yang W (2012) Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis 33, 326330.
  • 40
    Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B & Eichstetter I (1999) Cooperative action of germline mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci USA 96, 30923097.
  • 41
    Schaefer L & Iozzo RV (2012) Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr Opin Genet Dev 22, 5657.
  • 42
    Goldoni S, Humphries A, Nyström A, Sattar S, Owens RT, McQuillan DJ, Ireton K & Iozzo RV (2009) Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 185, 743754.
  • 43
    Reed CC, Gauldie J & Iozzo RV (2002) Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 21, 36883695.
  • 44
    Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, Owens RA, McQuillan DJ & Iozzo RV (2008) An anti-metastatic role for decorin in breast cancer. Am J Pathol 173, 844855.
  • 45
    Reed CC, Waterhouse A, Kirby S, Kay P, Owens RA, McQuillan DJ & Iozzo RV (2005) Decorin prevents metastatic spreading of breast cancer. Oncogene 24, 11041110.
  • 46
    Iozzo RV (1988) Proteoglycans and neoplasia. Cancer Metast Rev 7, 3950.
  • 47
    Santra M, Skorski T, Calabretta B, Lattime EC & Iozzo RV (1995) De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci USA 92, 70167020.
  • 48
    Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B & Iozzo RV (1997) Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 100, 149157.
  • 49
    Santra M, Eichstetter I & Iozzo RV (2000) An anti-oncogenic role for decorin: downregulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem 275, 3515335161.
  • 50
    Nash MA, Loercher AE & Freedman RS (1999) In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin. Cancer Res 59, 61926196.
  • 51
    Biglari A, Bataille D, Naumann U, Weller M, Zirger J, Castro MG & Lowenstein PR (2004) Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther 11, 721732.
  • 52
    Tralhão JG, Schaefer L, Micegova M, Evaristo C, Schönherr E, Kayal S, Veiga-Fernandes H, Danel C, Iozzo RV, Kresse H, et al. (2003) In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J 17, 464466.
  • 53
    Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, Owens RA, McQuillan DJ & Iozzo RV (2006) Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 281, 2640826418.
  • 54
    Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ & Iozzo RV (1998) Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 101, 406412.
  • 55
    Iozzo RV (1997) The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 32, 141174.
  • 56
    Patel S, Santra M, McQuillan DJ, Iozzo RV & Thomas AP (1998) Decorin activates the epidermal growth factor receptor and elevates cytosolic Ca2+ in A431 cells. J Biol Chem 273, 31213124.
  • 57
    Csordás G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, Nugent MA, Hajnóczky G & Iozzo RV (2000) Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem 275, 3287932887.
  • 58
    Albihn A, Johnsen JI & Henriksson MA (2010) MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 107, 163224.
  • 59
    Neill T, Painter H, Buraschi S, Owens RT, Lisanti MP, Schaefer L & Iozzo RV (2012) Decorin antagonizes the angiogenic network. Concurrent inhibition of Met, hypoxia inducible factor-1α and vascular endothelial growth factor A and induction of thrombospondin-1 and TIMP3. J Biol Chem 287, 54925506.
  • 60
    Hu Y, Sun H, Owens RT, Wu J, Chen YQ, Berquin IM, Perry D, O'Flaherty JT & Edwards IJ (2009) Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 11, 10421053.
  • 61
    Araki K, Wakabayashi H, Shintani K, Morikawa J, Matsumine A, Kusuzaki K, Sudo A & Uchida A (2009) Decorin suppresses bone metastasis in a breast cancer cell line. Oncology 77, 9299.
  • 62
    Shintani K, Matsumine A, Kusuzaki K, Morikawa J, Matsubara T, Wakabayashi T, Araki K, Satonaka H, Wakabayashi H, Lino T, et al. (2008) Decorin suppresses lung metastases of murine osteosarcoma. Oncol Rep 19, 15331539.
  • 63
    Buraschi S, Neill T, Owens RT, Iniguez LA, Purkins G, Vadigepalli R, Evans B, Schaefer L, Peiper SC, Wang Z, et al. (2012) Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft model. PLoS ONE 7, e45559.
  • 64
    Iozzo RV, Buraschi S, Genua M, Xu S-Q, Solomides CC, Peiper SC, Gomella LG, Owens RT & Morrione A (2011) Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem 286, 3471234721.
  • 65
    Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12, 159169.
  • 66
    Belfiore A, Frasca F, Pandini G, Sciacca L & Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30, 586623.
  • 67
    Belfiore A & Malaguarnera R (2011) Insulin receptor and cancer. Endocr Relat Cancer 18, R125R147.
  • 68
    Baker J, Liu J-P, Robertson EJ & Efstratiadis A (1993) Role of insulin-growth factor in embryonic and postnatal growth. Cell 75, 7382.
  • 69
    Liu J-P, Baker J, Perkins AS, Robertson EJ & Efstratiadis A (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor I (lgf-1) and type 1 IGF receptor (lgf1r). Cell 75, 5972.
  • 70
    Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, Rubin R, Efstratiadis A & Baserga R (1994) Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14, 36043612.
  • 71
    Garofalo G, Manara MC, Nicoletti G, Marino MT, Lollini P-L, Astolfi A, Pandini G, López-Guerrero JA, Schaefer K-L, Belfiore A, et al. (2011) Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 30, 27302740.
  • 72
    Malaguarnera R, Morcavallo A & Belfiore A (2012) The insulin and IGF-I pathway in endocrine gland carcinogenesis. J Oncol 2012, doi:10.1155/2012/635614.
  • 73
    Baserga R (2000) The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19, 55745581.
  • 74
    Lyons TR, O'Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW, Marusyk A, Tan A-C & Schedin P (2011) Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med 17, 11091115.
  • 75
    Morrione A, Valentinis B, Xu S-Q, Yumet G, Louvi A, Louvi A, Efstratiadis A & Baserga R (1997) Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci USA 94, 37773782.
  • 76
    Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A & Vigneri R (1999) Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19, 32783288.
  • 77
    Morcavallo A, Genua M, Palummo A, Kletvikova E, Jiracek J, Brzozowski AM, Iozzo RV, Belfiore A & Morrione A (2012) Indulin and insulin-like growth factor II differentially regulate endocytic sorting and stability of insulin receptor isoform A. J Biol Chem 287, 1142211436.
  • 78
    Schönherr E, Sunderkötter C, Iozzo RV & Schaefer L (2005) Decorin, a novel player in the insulin-like growth factor system. J Biol Chem 280, 1576715772.
  • 79
    Fiedler LR, Schönherr E, Waddington R, Niland S, Seidler DG, Aeschlimann D & Eble JA (2008) Decorin regulates endothelial cell motility on collagen I through activation of insulin-like growth factor I receptor and modulation of α2β1 integrin activity. J Biol Chem 283, 1740617415.
  • 80
    Johansson GS, Chisalita SI & Arnqvist HJ (2008) Human microvascular endothelial cells are sensitive to IGF-I but resistant to insulin at the receptor level. Mol Cell Endocrinol 296, 5863.
  • 81
    Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, Sorokin L, Gröne H-J, Reinhardt DP, Pfeilschifter J, Iozzo RV, et al. (2007) Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-1 receptor and mammalian target of rapamycin. Am J Pathol 170, 301315.
  • 82
    Iacob D, Cai J, Tsonis M, Babwah A, Chakraborty RN & Lala PK (2008) Decorin-mediated inhibition of proliferation and migration of the human trophoblast via different tyrosine kinase receptors. Endocrinology 149, 61876197.
  • 83
    Khan GA, Girish GV, Lala N, DiGuglielmo GM & Lala PK (2011) Decorin is a novel VEGFR-2-binding antagonist for the human extravillous trophoblast. Mol Endocrinol 25, 14311443.
  • 84
    Dyrskjøt L, Kruhøffer M, Thykjaer T, Marcussen N, Jensen JL, Møller K & Ørntoft TF (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64, 40404048.
  • 85
    Sanchez-Carbayo M, Socci ND, Lozano J, Saint F & Cordon-Cardo C (2006) Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24, 778789.
  • 86
    Metalli D, Lovat F, Tripodi F, Genua M, Xu S-Q, Spinelli M, Alberghina L, Vanoni M, Baffa R, Gomella LG, et al. (2010) The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol 176, 29973006.
  • 87
    Genua M, Xu S-Q, Buraschi S, Peiper SC, Gomella LG, Belfiore A, Iozzo RV & Morrione A (2012) Proline-rich tyrosine kinase 2 (Pyk2) regulates IGF-I-induced cell motility and invasion of urothelial carcinoma cells. PLoS ONE 7, e40148.
  • 88
    Iozzo RV & Schaefer L (2010) Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 277, 38643875.
  • 89
    Feugaing DDS, Tammi R, Echtermeyer FG, Stenmark H, Kresse H, Smollich M, Schönherr E, Kiesel L & Götte M (2007) Endocytosis of the dermatan sulfate proteoglycan decorin utilizes multiple pathways and is modulated by epidermal growth factor receptor signaling. Biochimie 89, 637657.
  • 90
    Monami G, Emiliozzi V & Morrione A (2008) Grb10/Nedd4-mediated multiubiquitination of the insulin-like growth factor receptor regulates receptor internalization. J Cell Physiol 216, 426437.
  • 91
    Moller AV, Jorgensen SP, Chen J-W, Larnkjaer A, Ledet T, Flyvbjerg A & Frystyk J (2006) Glycosaminoglycans increase levels of free and bioactive IGF-I in vitro. Eur J Endocrinol 155, 297305.
  • 92
    Arai T, Parker A, Busby W Jr & Clemmons DR (1994) Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. J Biol Chem 269, 2038820393.
  • 93
    Purushothaman A, Babitz A & Sanderson RD (2012) Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma. J Biol Chem 287, 4128841296.
  • 94
    Sanderson RD & Iozzo RV (2012) Targeting heparanase for cancer therapy at the tumor–matrix interface. Matrix Biol 31, 283284.
  • 95
    Garofalo C, Mancarella C, Grilli A, Manara MC, Astolfi A, Marino MT, Conte A, Sigismund S, Carè A, Belfiore A, et al. (2012) Identification of common and distinctive mehanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. Mol Endocrinol 26, 16031616.
  • 96
    Watson JA, Burling K, Fitzpatrick P, Kay E, Kelly J, Fitzpatrick JM, Dervan PA & McCann A (2008) Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder. Br J Urol Int 103, 694697.